NL
DE
Current HPV-DNA testing in population screening for cervical cancer might have had it best time. A new test originating from Radboudumc gives a decisive answer within four days.
Related news items
Third Radboudumc Investment Day again well-attended
16 October 2023On October 12, the Radboudumc Investment Day took place for the third time. Scientists, entrepreneurs and investors from the life sciences & health sector came together in the Radboudumc Experience Center to exchange knowledge, network and talk about new collaborations.
read more
Take Off 2 funding from NWO for Predica Diagnostics
30 June 2023Predica Diagnostics just secured the Take Off 2 funding to accelerate development of their cervical (pre)cancer prediction test.
read more
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Meet Healthy Ideas, Healthy Returns
2 June 2023Do you have a golden idea to improve healthcare, but not the resources to realize it? Discover Healthy Ideas, Healthy Returns: a Benelux-wide public-private network offering opportunities for healthcare investments and propositions, among other things.
read moreAftermovie Investment Day 2022 and a new date for 2023!
13 December 2022Over 100 scientists, investors, and entrepreneurs came together to accelerate innovation in healthcare by creating new business opportunities and forging strong public-private partnerships.
read more
Innovation by Predica Diagnostics BV improves cervical cancer screening
26 July 2022A joint financing round from ION+2 and the Thematic Technology Transfer Medtech Fund (TTT Medtech) allows the further development of molecular diagnostic tests for different cancers by Predica Diagnostics (Nijmegen, NL).
read more